Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Florida
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
ImmunityBio, Inc.
Sarcoma Oncology Research Center, LLC
Massachusetts General Hospital